Search research articles
Contact Us
Filters
Showing results (1201-1210 of 1,275) with videos related to
Page
of 128
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Genome Medicine
|
October 7, 2022
Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
Anna C F Lewis, Emma F Perez, Anya E R Prince, et al.
JACC. Cardiooncology
|
August 14, 2025
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy
Evaline Cheng, Maja Ivanovic, Antonia Chan, et al.
Circulation. Heart Failure
|
December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
Sanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
European Journal of Heart Failure
|
October 17, 2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
Javed Butler, Muhammad Shariq Usman, Kevin J Anstrom, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Journal of the American College of Cardiology
|
February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Douglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of Cardiac Failure
|
April 24, 2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial
Bradi B Granger, Lisa A Kaltenbach, Gregg C Fonarow, et al.
Page
of 128
Search research articles
Search
Showing results (1201-1210 of 1,275) with videos related to
Sort By:
Page
of 128
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Genome Medicine
|
October 7, 2022
Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
Anna C F Lewis, Emma F Perez, Anya E R Prince, et al.
JACC. Cardiooncology
|
August 14, 2025
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy
Evaline Cheng, Maja Ivanovic, Antonia Chan, et al.
Circulation. Heart Failure
|
December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
Sanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
European Journal of Heart Failure
|
October 17, 2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
Javed Butler, Muhammad Shariq Usman, Kevin J Anstrom, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Journal of the American College of Cardiology
|
February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Douglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of Cardiac Failure
|
April 24, 2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial
Bradi B Granger, Lisa A Kaltenbach, Gregg C Fonarow, et al.
Page
of 128